Drug intelligence / Profile preview

tulobuterol

Development stage
Phase 4
Lead developer
Hisamitsu Pharmaceutical
Modality
Small Molecules
Administration
Transdermal
01

Overview

Tulobuterol is a long-acting beta2-adrenergic receptor agonist used primarily as a bronchodilator for the management of asthma and chronic obstructive pulmonary disease (COPD). It works by selectively stimulating beta2-adrenergic receptors in bronchial smooth muscle, leading to muscle relaxation and airway dilation. This results in improved airflow and relief from symptoms such as wheezing, shortness of breath, and chest tightness. Tulobuterol is notable for its availability as a transdermal patch (Hokunalin tape), which provides sustained drug delivery over 24 hours with once-daily application. The patch formulation helps synchronize peak blood concentrations with periods of greatest need (e.g., morning dip in respiratory function) while minimizing systemic side effects[1][3][8]. Oral tablet forms are also available in some regions[6]. Tulobuterol has been approved since 1998 in Japan and is marketed in several countries including Japan, Germany, China, South Korea, Bangladesh, Pakistan, Venezuela, and India[3][8].

Brand names
Hokunalin tapeTulobuterol TapeTULOBUTEROL TAPE 2mg "NP"TULOBUTEROL TAPE 2mg "YP"
Other names
tulobuterol hydrochloride
02

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on tulobuterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tulobuterol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call